文献速递妇产影像

neoBona检测的性能:一种基于双端大规模并行鸟枪法测序的无细胞DNA非整倍体筛查新方法

Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening.
PubMed 文献 · Ultrasound Obstet Gynecol · 2017-02-28

本研究为盲法研究,对1000例孕11-13周接受胎儿21、18、13三体筛查孕妇的血浆样本(1mL)行双端大规模并行鸟枪法测序,同时评估胎儿分数、cfDNA片段大小分布与染色体计数并整合计算三体似然比(t-score)。结果显示988例(98.8%)获得有效结果,47例21三体、10例13三体、29/30例18三体及901例未受累病例均分类正确;新多组分t-score无需剔除胎儿分数<4%的样本,可能使更多孕妇受益于无创产前cfDNA分析。

要点

  • 双端大规模并行鸟枪法测序可同时评估胎儿分数、cfDNA片段大小分布与染色体计数。
  • 以t-score 1.5(21三体)和3.0(18/13三体)为染色体特异性切点分类三体与未受累。
  • 低胎儿分数(<1%)的三体与未受累病例仍可被正确识别。

核心结论

  • 基于双端大规模并行鸟枪法测序的cfDNA分析新方法可准确预测胎儿21、18、13三体;新多组分t-score无需剔除胎儿分数<4%的样本,可能将无创产前cfDNA分析的获益扩展至更大比例的妊娠。

研究设计与样本

  • 盲法研究,纳入1000例孕11-13周接受胎儿21、18、13三体筛查孕妇的血浆样本(1mL),其中21三体50例、18三体30例、13三体10例、未受累妊娠910例;采用neoBona®检测行双端大规模并行鸟枪法测序。

诊断标准与关键数值

  • 以染色体特异性t-score切点分类:21三体为1.5,18三体和13三体为3.0;988例(98.8%)获得有效结果,47例21三体、10例13三体、29/30例18三体及901例未受累病例分类正确;中位胎儿分数10.5%(范围0.3-33.8%),胎儿分数<1%的三体与未受累病例均被正确识别。

临床应用与阅片要点

  • 作者认为新多组分t-score无需剔除胎儿分数<4%的样本,可能将无创产前cfDNA分析的获益扩展至更大比例的妊娠。

局限性

  • 12例(1.2%)样本(9例整倍体、3例21三体妊娠)未通过质量控制标准而被排除进一步分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the performance of screening for fetal trisomies 21, 18 and 13 by cell-free (cf) DNA analysis of maternal blood using a new method based on paired-end massively parallel shotgun sequencing (MPSS).

METHODS: This was a blinded study of plasma samples (1mL) obtained from 1000 women undergoing screening for fetal trisomies 21, 18 and 13 at 11-13 weeks' gestation. The study included 50 cases with confirmed fetal trisomy 21, 30 with trisomy 18, 10 with trisomy 13 and 910 unaffected pregnancies. Paired-end MPSS with the neoBona® test allowed simultaneous assessment of fetal fraction, cfDNA fragment size distribution and chromosome counting, which were integrated into a new analysis algorithm to calculate trisomy likelihood ratios (t-score) for each chromosome of interest. Each sample was classified as trisomic or unaffected using chromosome-specific cut-offs set at t-score values of 1.5 for trisomy 21 and 3.0 for trisomies 18 and 13.

RESULTS: Valid results were provided for 988 (98.8%) cases; 12 (1.2%) samples, from nine euploid and three trisomy 21 pregnancies, did not pass quality-control criteria and were excluded from further analysis. All 47 cases of trisomy 21, all 10 of trisomy 13, 29 of 30 with trisomy 18 and all 901 unaffected cases were classified correctly. Median fetal fraction was 10.5% (range, 0.3-33.8%) and trisomic and unaffected cases with low fetal fractions of < 1% were identified correctly.

CONCLUSIONS: This novel method for cfDNA analysis of maternal plasma, which utilizes paired-end MPSS, can provide accurate prediction of fetal trisomies. Use of a new multicomponent t-score removes the need to reject samples with fetal fraction < 4%, which potentially extends the benefits of non-invasive prenatal cfDNA analysis to a larger proportion of pregnancies. © 2016 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cirigliano V, Ordoñez E, Rueda L, et al. Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening. Ultrasound Obstet Gynecol. 2017. PMID: 27981672. doi:10.1002/uog.17386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。